Claudio F Sturino

This inventor holds 24 USPTO granted patents and 9 published patent applications and 5 EPO patents, primarily in Pharmaceutical Innovations. Top assignees: Genentech, Inc., Merck Frosst Canada & Co., Vertex Pharmaceuticals, Inc.. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Claudio F Sturino. Retrieved from https://idiyas.com/inventor/claudio-f-sturino

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 9)

% Patents Active = 70.8

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 7.8

ph-index = 7

Forward Citations = 174(Granted Patents)

Location History:

Dorval, CA (2002)
L′ile-Bizard, CA (2009)
Laval, CA (2013)
Ile-Bizard, CA (2011 - 2018)
L'ile-Bizard, CA (2007 - 2019)
Montreal, CA (2020 - 2023)

Company Filing History:

Merck Frosst Canada & Co.

patents

5 out of 1,168

Vertex Pharmaceuticals, Inc.

patents

4. 2 out of 1,562

Boehringer Ingelheim International Gmbh

Merck Frosst Canada, Inc.

patents

8. 1 out of 2,405

Merck Sharp + Dohme Corp.

patents

9. 1 out of 110

Xenon Pharmaceuticals Inc.

patents

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

Broad Spectrum Antibiotics

Cystic Fibrosis Modulators

APOL1 Inhibitors

Transient Receptor Potential Channel

Therapeutic Compounds

HIV Replication Inhibitors

PAR-2 Signaling Pathway

EP4 Receptor Antagonists

Nitric Oxide Releasing Prodrugs

Cyclooxygenase-2 Inhibitors

PDE IV Inhibiting Amides

Cyclopentanoindoles

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12728129 - Macrocyclic broad spectrum antibiotics (2026-09-08),

2. 12324802 - Modulators of cystic fibrosis transmembrane conductance regulator (2025-06-10),

3. 12281102 - Inhibitors of APOL1 and methods of using same (2025-04-21),

4. 12269831 - Modulators of cystic fibrosis transmembrane conductance regulator (2025-04-08),

5. 12202824 - Oxadiazole transient receptor potential channel inhibitors (2025-01-21),

6. 12116343 - Inhibitors of APOL1 and methods of using same (2024-10-15),

7. 11655245 - Oxadiazole transient receptor potential channel inhibitors (2023-05-23),

8. 11208387 - Macrocyclic broad spectrum antibiotics (2021-12-28),

9. 11028075 - Therapeutic compounds and methods of use thereof (2021-06-08),

10. 10710994 - Oxadiazole transient receptor potential channel inhibitors (2020-07-14),

11. 10457654 - Therapeutic compounds and methods of use thereof (2019-10-29),

12. 10030024 - Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway (2018-07-24),

13. 9399645 - Inhibitors of HIV replication (2016-07-26),

14. 8685999 - Beta carboline sulphonylurea derivatives as EP4 receptor antagonists (2014-04-01),

15. 8349839 - Inhibitors of HIV replication (2013-01-08),

Title: Claudio F Sturino - Pioneering Inventor from L′ile-Bizard, CA

Introduction: Claudio F Sturino is a distinguished inventor hailing from L′ile-Bizard, Canada, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Claudio F Sturino holds several patents in various technological domains, showcasing his versatility and ingenuity in creating novel solutions to complex problems.

Career Highlights: Throughout his illustrious career, Claudio F Sturino has consistently pushed the boundaries of innovation, with a keen focus on developing cutting-edge technologies that have the potential to revolutionize industries.

Collaborations: Claudio F Sturino has collaborated with leading research institutions, universities, and companies to bring his inventions to life, fostering a culture of innovation and collaboration in the tech community.

Conclusion: Claudio F Sturino's relentless pursuit of innovation and his passion for creating transformative technologies have solidified his reputation as a visionary inventor in the vibrant landscape of Canadian innovation.

Profile summary based on public USPTO records.